Kilitch Drugs (India) Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 317.95 million compared to INR 299.72 million a year ago. Revenue was INR 347.51 million compared to INR 306.59 million a year ago. Net income was INR 29.09 million compared to INR 23.71 million a year ago. Basic earnings per share from continuing operations was INR 1.85 compared to INR 1.52 a year ago. Diluted earnings per share from continuing operations was INR 1.85 compared to INR 1.52 a year ago.
For the nine months, sales was INR 1,095.54 million compared to INR 941.22 million a year ago. Revenue was INR 1,135.61 million compared to INR 960.2 million a year ago. Net income was INR 110.07 million compared to INR 68.85 million a year ago. Basic earnings per share from continuing operations was INR 6.93 compared to INR 4.42 a year ago. Diluted earnings per share from continuing operations was INR 6.93 compared to INR 4.42 a year ago.